Desperate patients get early access to experimental cachexia drug
NCT ID NCT07399015
First seen Feb 19, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This program gives seriously ill adults with advanced pancreatic cancer and severe weight loss (cachexia) access to an experimental drug called mifomelatide before it is officially approved. It is for patients who have no other good treatment options for their weight loss and cannot join ongoing clinical trials. The goal is to help ease this debilitating symptom.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.